Cancer is characterized by an accumulation of genetic changes. Chromosomal abnormalities, including mutations, insertions, deletions, allelic losses of oncogenes and tumor suppressor genes, microsatellite alterations, hypermethylation of promoter genes have been discovered in cancer cell DNA. The application of molecular biological techniques, since the advent of the polymerase chain reaction (PCR), allows us to identify these alterations in tumors. The discovery of circulating DNA in the plasma opened the possibility to detect tumorrelated alterations in a medium which is in direct contact with all organs: blood.
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The nature of this circulating DNA was not known. It was postulated that it came either from the tumor itself or from lymphocytes reacting to the tumor. In 1989, we were able to show that this plasma DNA from cancer patients shared some biophysical properties (decreased strand stability) common to DNA of cancer cells and hence was of tumoral origin. 3 This approach was interesting but it required microgram amounts of DNA. Luckily PCR techniques became available allowing oncogene mutation detection in minute quantities.
The first mutational analyses performed on plasma DNA concentrated on the K-ras and N-ras oncogenes. [4] [5] [6] [7] [8] N-ras mutations have been found in DNA extracted from the bone marrow of patients with myelodysplastic syndrome and acute myelogenous leukemia (AML). These alterations have been examined in the plasma, leukocytes and bone marrow of such patients. 5 In patients with N-ras alterations, mutant DNA was always present in plasma DNA, though sometimes absent in the DNA of peripheral blood cells or bone marrow. This indicates that a single bone marrow biopsy or aspiration does not necessarily contain all the malignant clones involved in the disease and that plasma might be a suitable template for detecting alterations in patients suspected of having myelodysplastic syndrome or AML.
The second work on hematological disorders was done on B cell malignancies where rearranged Ig heavy chain DNA was detected in plasma or serum samples of patients. 9 Tumorderived clonal CDRIII DNA was found in serum or plasma in 47% of 110 patients with non-Hodgkin's lymphoma or acute B-precursor lymphoblastic leukemia. Follow-up showed a close correlation between persisting tumor-derived plasma/serum DNA and resistant disease or early relapse ( Table 1) .
The results suggested that the clinical significance of circulating tumor-derived DNA is different from that of DNA derived from peripheral blood cells, bone marrow or other tissues. Disappearance of amplifiable DNA from serum and plasma within days after the start of chemotherapy is intriguing. An increase of DNA would be expected such as can be observed with tumor-associated proteins after destruction of tumor cells. For the authors of the article, one explanation for this phenomenon would be that there is a steady balance between DNA release from cells and degradation by plasma nucleases. Interference with DNA replication may shift this balance towards degradation of DNA. Thus, disappearance of circulating DNA could be an indicator for successful chemotherapy in the sense of effective interference with DNA replication. The authors conclude by the remark that if circulating tumor-related DNA correlates with the presence of cells capable of DNA replication, a major question raised by current PCR studies for minimal residual disease (that is, the question of whether this DNA is derived from proliferating tumor cells or from differentiated cells or even cell debris) is less critical. The main fact remains that these results show that a positive PCR result in serum or plasma is highly predictive for resistance to treatment and impending relapse.
To our knowledge seven publications 4 report the presence of K-ras mutations in the circulating DNA corresponding to the mutation found in the tumor. In one of these studies, the authors have been able to follow-up a number of patients after surgery. 6 (1) Seventy-six patients with colorectal cancer or dysplastic colorectal adenoma, of which the plasma was analyzed pre-operatively, were followed up post-op for 18 months. 48.6% (37/76) had K-ras mutations in the primary tumor. The mutations were found in most serum DNA samples (86% correlation). Post op, K-ras mutations were found in the serum of five patients two of which developed a relapse. The plasma mutation detection predated the clinical recurrence by 1 year in one case. (2) Blood was taken from a second group of 47 patients who had been diagnosed with colorectal cancer in the past 5 years and who attended the hospital for conventional follow-up. Post-op serum mutant K-ras was detected in 9/31 (29%) of the cases with a mutation positive tumor. During follow-up, four of the nine cases have developed overt recurrent disease.
Pancreatic cancer differs from colorectal cancer in a number of important respects when it comes to detecting gene alterations in plasma. Firstly, pancreatic cancer can be difficult to differentiate from other conditions on the basis of clinical features and imaging investigations, so that a simple and non-invasive test would be especially valuable in this condition. Secondly, the K-ras gene is mutated in approximately 90% of pancreatic adenocarcinomas, suggesting that a comprehensive analysis of many genes would be unnecessary to detect the majority of cases. Five studies have therefore concentrated on detecting this gene in pancreatic cancer. 4 In one study, 7 plasma DNA was isolated from 21 pancreatic cancer patients and K-ras alterations detected by RFLP-PCR assay and subsequent product sequencing. Patients were followed up to determine their clinical outcome. K-ras mutations was found in the plasma of 17 patients (81%). In cases in which both plasma and pancreatic tissue were available, DNA mutations were similar in corresponding plasma and tissue samples. Plasma DNA alterations were found 5-14 months before clinical diagnosis in four patients who had been diagnosed as suffering from pancreatitis showing again that circulating tumor DNA may be an early event in oncogenesis. Mutant DNA was not found in the plasma of three patients with chronic pancreatitis who did not develop a carcinoma.
A follow-up study of patients with pancreatic adenocarcinoma also resulted in plasma DNA alterations being detected in a high proportion of cases in which a K-ras mutation was found in tumor tissue. 8 Patients with a K-ras gene mutation in plasma DNA had significantly larger tumors (P = 0.04) and less likely to result in a successful cure after surgical resection (P = 0.09) than those negative for the mutation. Treatment resulted in disappearance of K-ras gene mutations in plasma DNA in six of nine (67%) patients (Table 1) . Three patients with a persistently positive K-ras gene mutation in pre-and post-treatment plasma samples showed early recurrence or a progressive disease.
All tumors, however, do not have high mutation rates on easily testable hot spots. This is the reason why several groups looked for microsatellite alterations in the plasma/serum DNA of cancer patients. Microsatellite DNA is composed of simple repeats of unknown function. It is unstable in cancer cells and subject to alterations which appear as new alleles, allele expansion or loss of heterozygocity (LOH). Microsatellite DNA alterations are part of neoplastic progression and they may serve as clonal markers.
We initiated a study to detect microsatellite alterations in paired samples of plasma and tumor DNA from patients with small cell lung carcinoma compared to the same repeat sequences of normal cells from the same patients. A microsatellite alteration was present in 16/21 (76%) SCLC tumours and in 15 out of 21 (71%) corresponding plasma samples. 10 In a further study, 11 the correlation of abnormal plasma DNA with the survival of patients was investigated. Thirty-five patients with SCLC were selected. The same three markers (ACTBP2, UT762 and AR), as in the first study were used. Moreover, mutations of the TP53 gene in tumor and plasma DNA were checked. In 25/35 patients (71%), at least one molecular change precisely matching that of the primary tumor was detected in the plasma DNA. There was a correlation in 70% of cases in the clinical course of the disease between the response of tumors to treatment and the presence or disappearance of abnormal plasma DNA (Table 1) . This is well illustrated by the disappearance of DNA alterations after chemotherapy. Their reappearance or the appearance of DNA modifications in previously negative patients preceded the recurrence of the disease or coincided with it.
Microsatellite alterations were also found in the circulating DNA of head and neck cancer patients. 12 In this study, positive serum samples seemed to be related to patients with advanced disease, suggesting they may prove useful as prognostic factors.
Microsatellite alterations have also been detected in the circulating DNA of patients suffering from a variety of malignancies: non-small cell lung, 4 renal, 4 breast, 13 HNPCC and sporadic colon, 14 bladder cancers 15 and melanoma. 4, 15 The work on melanoma seems particularly promising not only for prognosis but also the detection of MRD and prediction of recurrence since a clear clinical correlation could be seen between the presence or absence of microsatellite imbalances and the progression of the disease. Indeed it was found that in 76 melanoma patients of different clinical stages, the frequency of DNA microsatellite markers with LOH was higher in more advanced stages of disease. Moreover at individual locus D3S1293, there was a clinical correlation of LOH with disease progression and the presence of metastases. Furthermore, several paired combinations of LOH markers in plasma were significantly correlated with stage and metastasis.
Other cancer-related markers have been reported in the circulating DNA of cancer patients such as EBV sequences 15 and promoter hypermethylation of several genes particularly p16. 4, [15] [16] [17] It is known that p16 mutations are rare but promoter hypermethylation resulting in gene inactivation are found to be common in a variety of different primary tumors. New markers are available since multiple genes are now known to be somatically inactivated by promoter hypermethylation. Because of a recently developed methylation specific PCR assay (MSP), sensitive detection of hypermethylated DNA can be carried out in plasma or serum. Twenty-two patients with non-small cell lung cancer were tested, 16 searching for promoter hypermethylation of the tumor suppressor gene p16, the putative metastasis suppressor gene death-associated protein kinase, the detoxification gene glutathione Stransferase P1, and the DNA repair gene O6-methylguanine-DNA-methyltransferase. Aberrant methylation of at least one of these genes was detected in 15 of 22 (68%) NSCLC tumors but not in any paired normal lung tissue. In these primary tumors with methylation, 11 of 15 (73%) samples also had abnormal methylated DNA in the matched serum samples. 16 Similarly, in the study of liver cancer, 17 p16 methylation was found in 73% (16/22) of hepatocellular carcinoma tissues. Amongst the 16 cases with aberrant methylation in the tumor, similar changes were also detected in the plasma/serum samples of 81% (13/16) of the cases. No methylated p16 sequences were detected in 38 patients with chronic hepatitis cirrhosis. Hypermethylation of p16 was also reported in tumor and plasma DNA of a series of breast. 13 Undoubtedly, as more methylated targets are found, other studies will follow in different tumor types.
What are the medical implications of circulating DNA? The data about this novel approach for cancer detection, prognosis and follow-up, are still preliminary from the clinical point of view. They seem nevertheless to be a promising pathway. DNA markers have the advantage of being qualitative (they are either absent or present) rather than quantitative such as proteins which also have the disadvantage of not being amplifiable. What are the implications of plasma DNA for clinical medicine? Firstly, the possibility of a non-invasive plasma DNA test for cancer diagnosis is challenging. Secondly, the association between mutant plasma DNA and tumor stage, the presence of residual disease and outcome suggests that it might potentially serve as a prognostic marker in the absence of clinically detectable metastases. Follow-up tests might be valuable in assessing response to therapy, identifying residual disease and recurrence at an asymptomatic and early stage.
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